Vaccine Technology Market

Vaccine Technology Market – Global Market Size, Strategic Growth Drivers, Risk Assessment Framework, Regulatory Landscape Review, Competitive Intensity Mapping & Long-Term Industry Outlook to 2030

10.3%

CAGR (2024-2030)

55.78 USD Bn.

Market Size

312

Report Pages

142

Market Tables

Overview

Vaccine Technology Market size is expected to grow at a CAGR of 10.3% during the forecast period and the market size is expected to reach nearly US$ 110.81 Bn. by 2030.

The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.To know about the Research Methodology:-Request Free Sample Report

Vaccine Technology Market Dynamics:

Vaccines play an important role in keeping us healthy. It is a biological preparation that provides active immunity to a particular disease. Vaccine market is growing rapidly because the most effective way to reduce infectious or non-infectious disease. Vaccines was first introduced in 1796 and from day onward it has become popular and necessity to every human being on planet. Vaccine technology has grown beyond limits and ongoing research, which is major factor in this market. If we consider research and development on many subjects, surprisingly they are making a huge difference in market analysis.

Vaccine Technology Market Segment Analysis:

Vaccines market are segmented into technology, disease, route, end user and type By technology it is segmented into conjugate, live, toxoid, recombinant. The conjugate vaccine is expected to lead in the market forecast period. Increasing government investments led to the growth of this segment.A new type of vaccines is inventing the monovalent vaccines is likely to be dominant in the market on the basis of type segment. Increase in awareness and product demand in developing countries is driving the market globally. High cost and restrictive process are the major restraints in the market.

Vaccine Technology Market, Research methodology:

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Vaccine Technology Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period.

PORTER’s analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Vaccine Technology Market.

Vaccine Technology Market, Key Highlights:

Global Market analysis and forecast, in terms of value.

Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Global Vaccine Technology Market

Global Market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided.

Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study.

Global Market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation.

Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled.

Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Global Market are also profiled.

Vaccine Technology Market, Key Target Audience:

Research and consulting firm as well as venture capitalistic, private equity firms, and startup companies
Vaccine design companies
Health organizations/associations
Hospital, physician and nursing home
Medical research laboratories
Vaccine supplier and manufacturer
Government and regulatory authorities

Market is categorized into the segments of Technology, Disease, Route, end user, Type and geography (region). Market value is estimated and forecasted with the revenues of leading companies operating in the vaccine market with key developments in companies and market trends.

Vaccine Technology Market Scope: Inquire before buying

Vaccine Technology Market
Report Coverage	Details
Base Year:	2023	Forecast Period:	2024-2030
Historical Data:	2018 to 2023	Market Size in 2023:	US $ 55.78 Bn.
Forecast Period 2024 to 2030 CAGR:	10.3%	Market Size in 2030:	US $ 110.81 Bn.
Segments Covered:	by Technology	Conjugate Live Toxoid Recombinant
	by Disease	Influenza DTaP HPV Hepatitis Rotavirus TT Polio MMR Varicella Dengue TB Rabies
	by Route	IM SC ID Oral
	by End-User	Pediatric Adult
	by Type	Monovalent vaccines Multivalent vaccine

Vaccine Technology Market, by Region:

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Vaccine Technology Market, Key Players are:

1. Pfizer Inc
2. Merck & Co., Inc
3. GlaxoSmithKline, plc
4. Sanofi Pasteur SA
5. Astellas Pharma Inc.
6. Emergent BioSolutions, Inc.
7. Serum Institute of India Pvt Ltd
8. Bavarian Nordic
9. Protein Science Corporation
10.Panacea Biotec
11.Daiichi Sankyo
12.CSL Limited
13.Medlmmune, LLC
14.Johnson & Johnson
15.Novartis AG
16.Janssen Pharmaceutical, Inc
17.Zydus Cadila
18.AstraZeneca
19.Mitsubishi Tanabe Pharma Corporation
20.Inovio Pharmaceuticals, Inc.

Frequently Asked Questions:

1. Which region has the largest share in Global Vaccine Technology Market?
Ans: Europe region holds the highest share in 2023.

2. What is the growth rate of Global Vaccine Technology Market?
Ans: The Global Vaccine Technology Market is growing at a CAGR of 10.3% during forecasting period 2024-2030.

3. What is scope of the Global Vaccine Technology market report?
Ans: Global Vaccine Technology Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Vaccine Technology market?
Ans: The important key players in the Global Vaccine Technology Market are – Pfizer Inc, Merck & Co., Inc, GlaxoSmithKline, plc, Sanofi Pasteur SA, Astellas Pharma Inc., Emergent BioSolutions, Inc., Serum Institute of India Pvt Ltd, Bavarian Nordic, Protein Science Corporation, and Panacea Biotec.

5. What is the study period of this market?
Ans: The Global Vaccine Technology Market is studied from 2023 to 2030.

1.EXECUTIVE SUMMARY 2. RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3. MARKET DYNAMICS 3.1. Market Drivers 3.2. Market Restraints 3.3. Market opportunities v4.1. Value Chain Analysis 4.2. Global Vaccine Technology Market Industry Trends and Emerging Technologies 5. GLOBAL VACCINE TECHNOLOGY MARKET, BY TECHNOLOGY (2023-2030) 5.1. Introduction 5.2. Conjugate 5.2.1. Conjugate Market Overview 5.2.2. Conjugate Size & Forecast 5.3. Live Technology 5.3.1. Live Technology Market Overview 5.3.2. Live Technology Size & Forecast 5.4. Toxoid 5.4.1. Toxoid Market Overview 5.4.2 Toxoid Size & Forecast 5.5. Recombinant 5.5.1. Recombinant Market Overview 5.5.2. Recombinant Size & Forecast 6. GLOBAL VACCINE TECHNOLOGY MARKET, BY DISEASE (2023-2030) 6.1. Introduction 6.2. Influenza 6.2.1. Influenza Market Overview 6.2.2. Influenza Size & Forecast 6.3. DTaP 6.3.1. DTaP Market Overview 6.3.2 DTaP Size & Forecast 6.4. HPV 6.4.1. HPV Market Overview 6.4.2. HPV Size & Forecast 6.5. Hepatitis 6.5.1. Hepatitis Market Overview 6.5.2. Hepatitis Size & Forecast 6.6. Rotavirus 6.6.1. Rotavirus Market Overview 6.6.2. Rotavirus Size & Forecast 6.7. TT 6.7.1 TT Market Overview 6.7.2. TT Size & Forecast 6.8. Polio 6.8.1. Polio Market Overview 6.8.2. Polio Size & Forecast 6.9. MMR 6.9.1. MMR Market Overview 6.9.2. MMR Size & Forecast 6.10. Varcella 6.10.1. Varcella Market Overview 6.10.2. Varcella Size & Forecast 6.11. Dengue 6.11.1. Dengue Market Overview 6.11.2. Dengue Size & Forecast 6.12. TB 6.12.1. TB Market Overview 6.12.2. TB Size & Forecast 6.13. Rabies 6.13.1. Rabies Market Overview 6.13.2. Rabies Size & Forecast 7. GLOBAL VACCINE TECHNOLOGY MARKET, BY ROUTE (2023-2030) 7.1. IM Route 7.1.1. IM Route Market Overview 7.1.1 IM Route Size& Forecast 7.2. SC Route 7.2.1. SC Route Market Overview 7.2.2. SC Route Size & Forecast 7.3. ID Route 7.3.1. ID Route Market Overview 7.3.2. ID Route Size & Forecast 7.4. Oral Route 7.4.1. Oral Route Market Overview 7.4.2. Oral Route Size & Forecast 8. GLOBAL VACCINE TECHNOLOGY MARKET, BY END USER (2023-2030) 8.1. Pediatric 8.1.1. Pediatric Market Overview 8.1.2. Pediatric Size & Forecast 8.2. Adult user 8.2.1. Adult user Market Overview 8.2.2. Adult user Size & Forecast 9. GLOBAL VACCINE TECHNOLOGY MARKET, BY TYPE (2023-2030) 9.1. Monovalent Vaccine 9.1.1 Monovalent Vaccine Market Overview 9.1.2. Monobalent Vaccine Size & Forecast 9.2. Multivalent Vaccine 9.2.1. Multivalent Vaccine Market Overview 9.2.2. Multivalent Vaccine Size & Forecast 10. GLOBAL VACCINE TECHNOLOGY MARKET, BY GEOGRAPHY (2023-2030) 10.1. North America Market 10.1.1. North America Global Vaccine Technology Market, by Technology 10.1.2. North America Global Vaccine Technology Market, by Disease 10.1.3. North America Global Vaccine Technology Market, by Route 10.1.4. North America Global Vaccine Technology Market, by End user 10.1.5. North America Global Vaccine Technology Market, by Type 10.1.6. North America Global Vaccine Technology Market, by Region 10.1.6.1. USA Global Vaccine Technology Market 10.1.6.2. Canada Global Vaccine Technology Market 10.2. Asia Pacific Global Vaccine Technology Market 10.2.1. Asia Pacific Global Vaccine Technology Market, by Technology 10.2.2. Asia Pacific Global Vaccine Technology Market, by Disease 10.2.3. Asia Pacific Global Vaccine Technology Market, by Route 10.2.4. Asia Pacific Global Vaccine Technology Market, by End user 10.2.5. Asia Pacific Global Vaccine Technology Market, by Type 10.2.6. Asia Pacific Global Vaccine Technology Market, by Region 10.2.5.1. China Global Vaccine Technology Market 10.2.5.2. Japan Global Vaccine Technology Market 10.2.5.3. South Korea Global Vaccine Technology Market 10.2.5.4. Australia Global Vaccine Technology Market 10.2.5.5. India Global Vaccine Technology Market 10.2.5.6. Rest of APAC Global Vaccine Technology Market 10.3. Europe Global Vaccine Technology Market 10.3.1. Europe Global Vaccine Technology Market, by Technology 10.3.2. Europe Global Vaccine Technology Market, by Disease 10.3.3. Europe Global Vaccine Technology Market, by Route 10.3.4. Europe Global Vaccine Technology Market, by End user 10.3.5. Europe Global Vaccine Technology Market, by Type 10.3.6. Europe Global Vaccine Technology Market, by Region 10.3.6.1. UK Global Vaccine Technology Market 10.3.6.2. Germany Global Vaccine Technology Market 10.3.6.3. France Global Vaccine Technology Market 10.3.6.4. Italy Global Vaccine Technology Market 10.3.6.5. Sweden Global Vaccine Technology Market 10.3.6.6. Spain Global Vaccine Technology Market 10.3.6.7. Russia Global Vaccine Technology Market 10.3.6.8. Rest of Europe Global Vaccine Technology Market 10.4. Middle East & Africa Global Vaccine Technology Market 10.4.1. Middle East & Africa Global Vaccine Technology Market, by Technology 10.4.2. Middle East & Africa Global Vaccine Technology Market, by Disease 10.4.3. Middle East & Africa Global Vaccine Technology Market, by Route 10.4.4. Middle East & Africa Global Vaccine Technology Market, by End user 10.4.5. Middle East & Africa Global Vaccine Technology Market, by Type 10.4.5. Middle East & Africa Global Vaccine Technology Market, by Region 10.4.5.1. GCC Countries Global Vaccine Technology Market 10.4.5.2. Israel Global Vaccine Technology Market 10.4.5.3. Rest of Middle East & Africa 10.5. Latin America Global Vaccine Technology Market 10.5.1. Latin America Global Vaccine Technology Market, by Technology 10.5.2. Latin America Global Vaccine Technology Market, by Disease 10.5.3. Latin America Global Vaccine Technology Market, by Route 10.5.4. Latin America Global Vaccine Technology Market, by End user 10.5.5. Latin America Global Vaccine Technology Market, by Type 10.5.6. Latin America Global Vaccine Technology Market, by Region 10.5.6.1. Brazil Global Vaccine Technology Market 10.5.6.2. Argentina Global Vaccine Technology Market 10.5.6.3. Rest of Latin America Global Vaccine Technology Market 11. MARKET COMPETITION ANALYSIS 11.1 Strategy Framework 11.2 Company Profile 11.2.1 Pfizer Inc 11.2.1.1 Company overview 11.2.1.2 Financial performance 11.2.1.3 Product benchmarking 11.2.1.4 Strategic initiatives 11.2.2 Merck & Co., Inc 11.2.2.1 Company overview 11.2.2.2 Financial performance 11.2.2.3 Product benchmarking 11.2.2.4 Strategic initiatives 11.2.3 GlaxoSmithKline, plc 11.2.3.1 Company overview 11.2.3.2 Financial performance 11.2.3.3 Product benchmarking 11.2.3.4 Strategic initiatives 11.2.4. Sanofi Pasteur SA 11.2.4.1 Company overview 11.2.4.2 Financial performance 11.2.4.3 Product benchmarking 11.2.4.4 Strategic initiatives 11.2.5 Astellas Pharma Inc. 11.2.5.1 Company overview 11.2.5.2 Financial performance 11.2.5.3 Product performance 11.2.5.4 Strategic initiatives 11.2.6 Emergent BioSolutions, Inc. 11.2.6.1 Company overview 11.2.6.2 Financial performance 11.2.6.3 Product performance 11.2.6.4 Strategic initiatives 11.2.7 Serum Institute of India Pvt Ltd 11.2.7.1 Company overview 11.2.7.2 Financial performance 11.2.7.3 Product performance 11.2.7.4 Strategic initiatives 11.2.8 Bavarian Nordic 11.2.8.1 Company overview 11.2.8.2 Financial performance 11.2.8.3 Product performance 11.2.8.4 Strategic initiatives 11.2.9 Protein Science Corporation 11.2.9.1 Company overview 11.2.9.2 Financial performance 11.2.9.3 Product performance 11.2.9.4 Financial performance 11.2.10. Panacea Biotec 11.2.10.1 Company overview 11.2.10.2 Financial performance 11.2.10.3 Product performance 11.2.10.4 Financial performance 11.2.11. Daiichi Sankyo 11.2.11.1 Company overview 11.2.11.2 Financial performance 11.2.11.3 Product performance 11.2.11.4 Financial performance 11.2.12. CSL Limited 11.2.12.1 Company overview 11.2.12.2 Financial performance 11.2.12.3 Product performance 11.2.12.4 Financial performance 11.2.13. Medlmmune, LLC 11.2.13.1 Company overview 11.2.13.2 Financial performance 11.2.13.3 Product performance 11.2.13.4 Financial performance 11.2.14. Johnson & Johnson 11.2.14.1 Company overview 11.2.14.2 Financial performance 11.2.14.3 Product performance 11.2.14.4 Financial performance 11.2.15. Novartis AG 11.2.15.1 Company overview 11.2.15.2 Financial performance 11.2.15.3 Product performance 11.2.15.4 Financial performance 11.2.16. Janssen Pharmaceutical, Inc 11.2.16.1 Company overview 11.2.16.2 Financial performance 11.2.16.3 Product performance 11.2.16.4 Financial performance 11.2.17. Zydus Cadila 11.2.17.1 Company overview 11.2.17.2 Financial performance 11.2.17.3 Product performance 11.2.17.4 Financial performance 11.2.18. AstraZeneca 11.2.18.1 Company overview 11.2.18.2 Financial performance 11.2.18.3 Product performance 11.2.18.4 Financial performance 11.2.19. Mitsubishi Tanabe Pharma Corporation 11.2.19.1 Company overview 11.2.19.2 Financial performance 11.2.19.3 Product performance 11.2.19.4 Financial performance 11.2.20. Inovio Pharmaceuticals, Inc. 11.2.20.1 Company overview 11.2.20.2 Financial performance 11.2.20.3 Product performance 11.2.20.4 Financial performance

Choose License Type